NORML
MAY 26, 2020
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
NORML
FEBRUARY 25, 2020
Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinical trial data published in the journal Trauma Surgery & Acute Care. Additional information on the relationship between cannabis and opioids is available in the NORML fact-sheet here.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NORML
MAY 21, 2019
.'” The abstract of the study, “Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo controlled trial,” appears online here.
NORML
APRIL 30, 2020
” This finding is hardly a surprise, as cannabis is well-established to mitigate pain in clinical models, particularly in patients with neuropathy. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display.”
Cannabis Law Report
JULY 21, 2021
The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.
NORML
MARCH 30, 2020
By contrast, they reported that there exists “no evidence from properly designed clinical trials to support the use of CBD for the treatment” of these or other conditions, such as the flu, West Nile virus, Ebola, or common cold viruses. However, this data was based solely on preclinical findings.
Cannabis Law Report
JUNE 16, 2021
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. . This relationship enables us to initiate our clinical research program and marks an important step for Wake in Canada. ABOUT WAKE NETWORK, INC.
Expert insights. Personalized for you.
272 
Let's personalize your content